Onward

EPFL spin-off ONWARD is helping paralysed spinal cord injury patients regain important functions, thanks to groundbreaking neurostimulation technologies. Based on world-leading research, impressive pre-clinical results and a network of key opinion leaders, ONWARD has developed two platforms that use the same principle. They electrically stimulate the patients’ nerves to re-establish body functions that will help patients lead a more independent and improved life. Tests have shown that ONWARD’s technology promotes neuroplasticity, i.e. the stimulation leads to an improvement in movement patterns even after it is turned off. ONWARD is working to enable patients to move again, for some this might mean regaining basic functions to feed or dress themselves, for others, it could even mean resuming complex tasks such as walking or playing the guitar.
Onward_colour- Verve Ventures portfolio
ONWARD listed on Euronext Brussels in 2021
On 21 October, ONWARD completed an Initial Public Offering (IPO) on Euronext, raising over USD 100M (EUR 86M). This is believed to be the largest early-stage medical device IPO in European history.
Founders / Management Dave Marver
Sectors Health & Bio, MedTech
Located in Eindhoven, Netherlands
Co-Investors btov, Wellington Partners, INKEF Capital
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.